Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 13/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 10/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838068 | 0.83 | PTPN1 (0.43) | PTPN1PTPN2GLO1MAPTKLKB1 | |
| SCHEMBL7521067 | 0.83 | PTPN1 (0.47) | PTPN1PTPN2GLO1MAPT | |
| SCHEMBL7525127 | 0.82 | PTPN1 (0.47) | PTPN1PTPN2GLO1MAPTMEN1 | |
| SCHEMBL7522308 | 0.81 | GLO1 (0.46) | PTPN1PTPN2GLO1MAPTPPARA | |
| SCHEMBL7519093 | 0.80 | PTPN1 (0.46) | PTPN1PTPN2MAPTDRD2 | |
| SCHEMBL7526850 | 0.80 | PTPN1 (0.46) | PTPN1PTPN2GLO1MAPTDRD2 | |
| SCHEMBL7520436 | 0.79 | PTPN1 (0.38) | PTPN1PTPN2MAPTKLKB1 | |
| SCHEMBL7521500 | 0.78 | PTPN1 (0.43) | PTPN1PTPN2GLO1KMT2A | |
| SCHEMBL7515843 | 0.77 | KDM4E (0.45) | PTPN1MAPTKMT2A | |
| SCHEMBL5838091 | 0.77 | PTPN1 (0.53) | PTPN1PTPN2GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-07-25 | — | — | US | claimed |
| WO-2002004458-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-01-17 | — | — | WO | claimed |
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | NOVO NORDISK A/S (DK) | 2002-07-25 | — | — | US | disclosed |
| WO-2002004458-A1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK A/S (DK) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099073-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPN1, PTPRO, PTPRS | PTPN1 1/4885PTPN2 14/4885GLO1 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.